A LinkedIn post from Glooko describes new clinical data presented at the 2026 American Association of Clinical Endocrinology Annual Meeting. According to the post, Glooko’s EndoTool IV, developed by Monarch Medical Technologies, was associated with a 98% reduction in severe hypoglycemia compared with paper protocols across Advocate Health’s 19-hospital system.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights the potential of EndoTool IV to support safer inpatient glycemic management at health-system scale. For investors, these results may indicate strengthening clinical validation for Glooko’s technology, which could support wider health-system adoption, enhance recurring software and services revenue potential, and improve the company’s competitive position in hospital glycemic management solutions.
The association with a large multi-hospital network such as Advocate Health also suggests exposure to enterprise-level purchasing decisions. If similar outcomes are reproduced in other systems, this could create a data-driven basis for value-based contracting and support pricing power versus traditional paper-based or less automated approaches in inpatient diabetes care.